Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER/neu

Journal of Surgical Research

Volumn 77, Issue 1, 1998, Pages 85-90

  Roh, Haeri ^a   Pippin, James ^a   Boswell, Craig ^a,b   Drebin, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Antisense; Breast cancer; HER2; Neu; Oligonucleotide; Oncogene

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE PROTEIN; FLUORESCEIN ISOTHIOCYANATE; MESSENGER RNA; ONCOPROTEIN; PHOSPHOROTHIOIC ACID DERIVATIVE;

ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NORTHERN BLOTTING; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0031904608     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5353     Document Type: Article

References (30)

1. r tumor antigen. Nature 312: 513, 1984.
2. Schechter, A. L., Hung, M-C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U. L., Ullrich, A., and Coussens, L. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976, 1985.
3. Coussens, L., Yang-Feng, T. L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132, 1985.
4. Carraway, K. L., and Cantley, L. C. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78: 5, 1994.
5. Graus-Porta, D., Beerly, R. R., Daly, J. M., and Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is the mediator of lateral signaling. EMBO J. 16: 1647, 1997.
6. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta 1198: 165, 1994.
7. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. C., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707, 1989.
8. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKinzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50: 4087, 1990.
9. HER2 expression in human non-small cell lung cancer cell lines. Am. J. Respir. Cell Mol. Biol. 6: 359, 1992.
10. Williams, T. M., Weiner, D. B., Greene, M. I., and McGuire, H. C. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59: 46, 1991.
11. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 695, 1985.
12. Drebin, J. A., Link, V. C., Weinberg, R. A., and Greene, M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 83: 9129, 1986.
13. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165, 1989.
14. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14: 737, 1996.
15. Graus-Porta, D., Beerli, R. R., and Hynes, N. E. Single chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15: 1182, 1995.
16. Brodowicz, T., Wiltschke, C., Budinsky, A. C., Krainer, M., Steger, G. G., and Zielinski, C. C. Soluble HER2/neu neutralizes biologic effects of anti-HER2/neu antibody on breast cancer cell in vitro. Int. J. Cancer 73: 875, 1997.
17. c-erbB2: Increased invasiveness may contribute to poor prognosis. Clin. Cancer Res. 3: 1629, 1997.
18. Zamecnik, P. C., and Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75: 280, 1978.
19. Stein, C. A., and Krieg, A. M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4: 67, 1994.
20. Wagner, R. W. The state of the art in antisense research. Nature Med. 1: 1116, 1995.
21. Crooke, S. T., and Bennett, C. F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36: 107, 1996.
22. Vaughn, J. P., Iglehart, J. D., Demirdji, S., Davis, P., Babiss, L. E., Caruthers, M. H., and Marks, J. R. Antisense DNA downregulation of the ErbB2 oncogene measured by a flow cytometric assay. Proc. Natl. Acad. Sci. USA 92: 8338, 1995.
23. HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37: 255, 1993.
24. Liu, X., and Pogo, B. G.-T. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 6: 9, 1996.
25. Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K-H., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J. Natl. Cancer Inst. USA 89: 1027, 1997.
26. Anfossi, G., Gewirtz, A. M., and Calebretta, B. An oligomer complementary to c-myb encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA 86: 3379, 1989.
27. Leonetti, D., D'Agnano, I., Lozupone, F., Valentini, A., Geiser, T., Zon, G., Calebretta, B., Citro, G., and Zupi, G. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst. USA 88: 419, 1996.
28. Cho-Chung, Y. S., Nesterova, M., Kondrashin, A., Noguchi, K., Srivastava, R., and Pepe, S. Antisense-protein kinase A: A single-gene-based therapeutic approach. Antisense Nucleic Acid Drug Dev. 7: 217, 1997.
29. Glazer, R. I. Protein kinase C as a target for cancer therapy. Antisense Nucleic Acid Drug Dev. 7: 235, 1997.
30. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2: 668, 1996.